Source - SMW
Mereo BioPharma Group said the European Medicines Agency has granted a treatment for brittle bone disease as a priority medicine. 

The disease, technically known as osteogenesis imperfecta, is a debilitating condition for which there is no current treatment approved by the U.S. Food and Drug Administration or the EMA. 

Mereo announced commencement of a Phase 2b trial for treatment BPS-804 in adult patients with the condition in May 2017.




At 9:41am: (LON:MPH) Mereo Biopharma Group Ltd share price was +2.5p at 325p



Related Charts

Mereo Biopharma Group (MPH)

0.00p (0.00%)
delayed 16:57PM